Found 84 articles
Expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries
CereHealth Showcases "Going Against the Norm" During the Society of Nuclear Medicine and Molecular Imaging's Annual Meeting
CereHealth Corp., a recognized leader and innovator in biotechnology applications and advanced neurodiagnostics, announced today that its FDA-cleared population template, an alternative to traditional normative datasets for quantitative analysis of clinical brain SPECT, will be presented by the company's Senior Medical Imaging Engineer, Lindsay Quandt, MS, MBA, at SNMMI's Annual Meeting on July 11-14
Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19
Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the successful synthesis of a readily-scalable live-attenuated vaccine candidate against COVID-19. The vaccine, CDX-005, is currently undergoing safety and efficacy studies in animals and appears m
New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025
International Osteoporosis Foundation Announces First-of-its-kind Partnership With University of Oxford, Amgen and UCB to Combat Global Public Health Burden of Osteoporosis
Researchers have been working furiously to identify medications to combat the novel coronavirus that causes COVID-19.
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million.
Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University Phase 2b clinical efficacy study
Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19
FARMINGDALE, N.Y. , Feb. 13, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this nov
Hoverink Biotechnologies, Inc., today announced Hoverink CEO Debbie Carter Steps Down; Cyrus Sajna Appointed as her Successor
Hoverink Biotechnologies announced today that CEO Debbie Mae Carter will step down and will be succeeded by Cyrus Sajna as CEO and CFO of the company.
Aragen Bioscience, Inc and Serum Institute of India Pvt. Ltd. are pleased to announce a collaboration for the development of multiple stable cell lines to support Serum’s HIV program.
BioDuro, LLC, a leading global life sciences contract research, development and manufacturing services organization, is pleased to announce the appointment of Kent Payne, Ph.D., as President of its CMC Global Solutions business unit.
Although there have been numerous variations on CRISPR that improve its effectiveness and apparent safety, there are still concerns about off-target edits and immune reactions to the Cas9 enzyme used to cut DNA.
Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology
Cyrus Biotechnology, Inc., and the Broad Institute of MIT and Harvard have embarked on a scientific collaboration to optimize CRISPR for use in developing novel human therapeutics.
Biocon Ltd, an innovation-led global biopharmaceuticals company, is pleased to announce that its Chairperson & Managing Director Kiran Mazumdar-Shaw has been conferred with the Lifetime Achievement Award for Outstanding Achievement in Healthcare by the Indian Council of Medical Research (ICMR) for her remarkable contribution to the field of healthcare and to the society at large
Cyclo Therapeutics Announces Its Publication of the Most Extensive Set of Case Study Reports To-Date on Expanded Access Use of Hydroxypropyl Beta Cyclodextrin in Niemann-Pick Disease Type C
Publication describes favorable safety profile and efficacy in neurologic and other disease features in individual NPC patients following intravenous administration of drug
Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology
Aridis Pharmaceuticals, Inc. announced that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV and the Serum Institute of India, Ltd.
Cyrus Biotechnology Offers CryoEM Services Based on First-in-class, Peer-reviewed Rosetta Software Methods
Cyrus Biotechnology, Inc. announces the availability of CryoEM services to generate high precision models from CryoEM data.
Cyrus Biotechnology Significantly Expands Customer Engagement through Biotherapeutic Partnerships and Fee-for-Service Scientific Consulting
Cyrus Bench customers will be able to expand their relationship with Cyrus to tackle a broader set of challenges through Cyrus fee-for-service scientific consulting.
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology
Aridis Pharmaceuticals, Inc. announced that it has entered into an option agreement with the Serum International BV, an affiliate of Serum Institute of India, Ltd., the world's largest vaccine manufacturer by dose units.
5/30/2019Here's a preview of just a handful of opportunities, companies and speakers and what they’re presenting.